there's ban litteen a little pe allerai algeon the one who will tell the most is amgen >> amgen >> amgenat migraine drug fabulous -- a fabulous pipeline. amgen is unable to tell its story. >> and that's because they choose to be uniquely unable to do that or they're inarticulate? >> damned if i know. >> they just can't tell it but you'll help them >> i am. i have a business plan. >>> chevron and exxon helping the dow owut intel a laggard. china at the center of this. >> she's terrific, she's trying to make the case that the service revenues will help, they deserve a higher multiple. i remember when she raised, they didn't see this. everybody makes mistakes, including the fed. i look at her timeframe. morgan stanley, previous price target, 2.53 she had gone from 2.26 to 2.53 >> to her defense, several suppliers have warned since that call in november >> yes >> china's real weakness you hope it is apparently style the way people buy, and not a boycot boycott. >> we don't know >> we don't. we don't >> there hasn't been a widespread call for a boycott of apple products >> no. >> let's not fo

amgen is not hyped this was a remarkable test that was revealed i realize that amgen is as good as anythingat came out of this conference. people have to focus on the new formulation that amgen is making it is traumatic. when you add this onto their revolution migraine truck and you put it up with rapatha, its got a huge amount of cash, too >> yes, it does. people focused it on some time and they brought it back >> i think people did not look at this. they did not read the paper. i read the paper over the eagles win with sanchez the guy knows how to fumble. he's not going to make it so what's the point >> well, that's maybe a good point. >> this is not sanchez >> this is wentz not sanchez. >> got it. >> okay, it is not mahomes >> all right i understand you are not winning the super bowl this year either, keep in mind >> david, it is early. >> it is early although we got an opening bell ayitusnus omowmitefr n st wh ♪ ♪ ♪ ♪ ♪ the difference between possible and impossible? it's a person who believes they can, surrounded and supported by others - by us - who believe it, too u.s. bank - the pow

level, one of the rationales in the space in general is the valuations of the underlying businesses, amgen, gilead, celgene. they're selling at relatively cheap multiples. i feel like that serves as a little bit of a back stop. this is a basket of stocks the options aren't overly expensive. especially given how volatile this has been and how stocks have been recently i'm looking at january and looking at the 108 and 33 cent strike calls that seems strange, right? but only because sometimes you get the strike adjustments this is just a standard contract like any other that happens to be the nearest out of the money strike those are going to cost you $4 so you're risking approximately 4% of the underlying price here to make a bullish bet. look, one of the things that can happen here is that you have some time until january expiration if it does run we'll have some opportunities to either roll this or potentially spread it so there are things to do here. i think that's a simple way we can make a bullish bet here. >> they have to make a lot of cash on the balance sheets still. >> so it's inter

novartis 14% of tear drugs, amgen, bayer, gsk, will all see increases. 5% is a lot if you're consumera co-pay. connell: you would be in favor, i don't know if you would, free market as a general theme but in this case, what are we going to see? the government will crack down and president himself has been pushing for that shaming of the companies is not going to do it? >> i think price transparency the first step. we're seeing a lot more of that. dashboards on medicare, medicaid, consumer angrily seeing what they're paying which manufacturer is raising prices the most. california has a law if you raise prices more than six 10% it has got to be reported. we need more and more of that. connell: okay. >> ultimately competition will rule the day. you're right, shaming will if the president is watching he will shame more. we need more pressure from hhs. connell: a lot on his plate. i'm not sure if he gets on it. dr. siegel. thank you. >> good to see you. >> speaking what is on the president's plate and everybody's plate. the market up and down we go. 340 to the downside. down 600 plus a li

home ♪ david: reuters is reporting that nearly 30 big drug companies including bayer, novartis and amgen posing a new challenge to president trump's pledge to lower the cost of prescription medications. is this going to make senator warren's idea of creating this government drugmaker more appealing? what do you think? >> i think there is no way this idea of the government producing and also pricing drugs makes any sense whatsoever. all she needs to do is go to china, go to russia. look how state-owned enterprises almost always get it wrong, end up making things much more expensive and, basically, the taxpayer pays for it. i'm kind of shocked, actually, with the drug chain and system being so complicated that she would offer up such a sort of hare-brained idea. >> first of all, medical care is very cheap in russia, i would just make that note. [laughter] david: to stay alive. >> the travesty of elizabeth warren trying to grab attention in her bid for running for president, there is a serious role for the government who's sat on the sidelines and has actually caused some of the problems in

i amgen fer casarian and i work here at san francisco international airport.he idea for therapy dogs got started the day after 9/11. an employee brought his therapy dog to work after 9/11 and he was able to see how his dog was able to relieve passenger's jitter. when we first launched the program back in 2013, our main goal was to destress our passengers however what we quickly found is that our animals were helping us find a way to connect with our pang. passengers. we find there are a lot of people traveling through the airport who are missing their pets and who are on their road a lot and can't have pets and we have come in contact with a lot of people recently who have lost pet. >> i love the wag brigade. >> one of my favorite parts is walking into the terminals and seeing everybody look up from their device, today everybody is interacting on their cell phone or laptop and we can walk into the terminal with a dog or a pig and people start to interact with each other again and it's on a different level. more of an emotional level. >> i just got off an 11.5

think of an amgen, activities with balance sheet capacity.ng so quickly gilead, for example, has suffered are these the kind of acquires that we should imagine >> biotech generally, an amazing amount of science and growth and there's a new way of unicorns that have come into biotech. you see big pharma historically, now you see the same thing, their growth is tapering big market companies to drive their pipeline. >> you're an old health care banker from a long time back are we ever going to see the likes of consolidation that we saw in the '90s? >> one or two big deals are left that could happen. i'm not sure they will happen. the only headwind around m & a with all the transactions is regulatory and it's uncertainty around regulatory and this wave of nationalism and protectionism. big pharma companies that could consolidate, they have characteristics of nationalistic champions that i'm not sure you'll see what we saw in the '90s. >> pulling money out of the market in m & a, what about putting it in, as in ipos? you're not an m & a guy. a lot

earnings ratio and they rehired chip and joanna, who are america's darlings bank of america, jpmorgan, amgenust raised their dividend and higher than a ten-year treasury and trades at a very reasonable multiple >> brad, quick question for you. i see you think growth will moderate next year 2, 2.5% inflation will not be a risk stocks often perform well with modest growth and modest inflation. >> i think that's exactly right. i'm actually looking to see maybe 10% gains next year for the s&p 500. we don't have to do a lot there. just see earnings grow about where they're expected to and valuations stay where they are right now. which is pretty close to the lows of the last five years. that's not an aggressive call. that's a very reasonable call. there are some opportunities out there. >> all right, folks, thank you very much. bill smead and brad mcmillan with commonwealth. >> you both gain -- >> my wife is for sure >> i want to see what they do with this channel if they launch this magnolia channel. >>> sources close to the investigation of the marriott hotel hack said carried out by china. wha

allergan, glaxosmithkline, amgen, astrazeneca, bio again reporting to plan price increases in 2019.hit patients who this year, by the way spent over $360 billion on prescriptions that is a 6% increase over last year. many health care officials will argue that consumers don't feel the increases because of rebates and discounts that are offered but the ceo of eli lilly disagrees. >> drug price inflation reported last year in the u.s., .4%. so we don't have a drug price increase problem to the system. we have a drug price increase problem to the patient. why? because they're paying list prices. >> insurance has consumers paying full price rather than the negotiated price. neil, as you know, this has political ramifications for 2020. it is actually a bipartisan issue but lowering prescription drug prices is what president trump promised us back in 2016. neil: thank you very much, lauren simonetti. just an update right now happening as we speak at the white house. the president is meeting with republican leaders, including outgoing speakers paul ryan. ned ryan here no relation to the spe

50s i'm talking a couple years ago now made the round trip almost back to $32 and change shares of amgening are something to maybe keep an eye on the company's myeloma treatment drug received a fast track designation from the fda the company said seven of ten patients given the second highest form >>> and waste management got two upgrades actually a two move upgrade from one company goldman sachs which moved the waste processing company all the way to buy from sell i don't know >> that was cheaper a month ago. >> i don't know how you do that on valuation do you, santoli? >> purely on the valuation no >> look. on valuation, in other words we were totally wrong how we valued it i guess. also raised the price target on the stock. >>> and a potential pot deal in the work cronos confirms they're in talks with altria. shares are up another 8% premarket. actually, 10% right now. cronos says no deal has been reached and there's no word that it will lead to any transaction. the talks come as altria is looking to go beyond traditional smokers. sha shares of altria down 22% this year >>> wilbur ros